Conquering Diseases

Investigation Of Cs1003 Or Placebo In Combination With Lenvatinib Subjects With Advanced Hepatocellular Carcinoma (Hcc)


Seeking men and women 18-75 years of age with a type of liver cancer called advanced hepatocellular carcinoma (HCC) for participation in a study of an investigational drug called CS1003, or a placebo, in combination with the standard treatment.


We are studying the effects of an investigational drug named CS1003 and its safety for patients with HCC.

What we're hoping for

To evaluate the how well CS1003 works, how safe it is, and how well it is tolerated in addition to the standard treatment for this type of cancer.

Additional Information Identifier: NCT04194775

 Principal Investigator

Patan  Gultawatvichai, MD

UMass Memorial Health Care

 Study Contact

The Cancer  Research Office



UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655